Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of vafidemstat in borderline personality disorder (BPD)

Next Previous
Trial Profile

A Phase III study of vafidemstat in borderline personality disorder (BPD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Borderline personality disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms PORTICO-2
  • Sponsors Oryzon

Most Recent Events

  • 23 Jun 2025 According to an Oryzon media release, company announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD).
  • 12 May 2025 According to an Oryzon media release, PORTICO-2 Phase III study has the potential to be one of the two registrational trials required by the FDA.
  • 03 Mar 2025 According to an Oryzon media release, announced that it has established the primary and key secondary endpoints for its planned Phase III clinical trial, aligned with FDA standards.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top